Cargando…
Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers
BACKGROUND: Tislelizumab is an anti-programmed cell death 1 (PD-1) monoclonal antibody engineered to minimize binding to Fcγ receptors. It has been used to treat several solid tumors. However, its efficacy and toxicity, and the predictive and prognostic value of baseline hematological parameters in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975598/ https://www.ncbi.nlm.nih.gov/pubmed/36875089 http://dx.doi.org/10.3389/fimmu.2023.1113369 |